Where Gilead Sciences Stands With Analysts
GILDOver the past 3 months, 11 analysts have published their opinion on Gilead Sciences (NASDAQ:GILD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
BMO Capital Maintains Market Perform on Gilead Sciences, Lowers Price Target to $63
GILDPiper Sandler Maintains Neutral on Gilead Sciences, Raises Price Target to $73
GILDGilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus
GILDGilead Sciences, Inc. (NASDAQ: GILD) reported firs
Recap: Gilead Sciences Q1 Earnings
GILDGilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM.
Here's what investors need to know about the announcement.
Gilead Sees FY22 Adj. EPS $6.20-$6.70 vs $6.50 Estimate, Sales $23.8B-$24.3B vs $24.5B Est.
GILDGilead Sciences Q1 EPS $2.12 Beats $1.80 Estimate, Sales $6.60B Beat $6.28B Estimate
GILD